MOA of entacapone

Mechanism of Action of Entacapone

by

Introduction

Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct therapy in Parkinson’s disease, particularly in patients experiencing end-of-dose “wearing-off” phenomena with levodopa. It enhances and prolongs the effect of levodopa by reducing its peripheral metabolism. Entacapone is a high-yield drug in pharmacology and neurology examinations because of its enzyme inhibition–based mechanism and its role in optimizing dopaminergic therapy.

Mechanism of Action (Step-wise)

Entacapone acts by inhibiting peripheral metabolism of levodopa, increasing its bioavailability to the brain.

  1. Dopamine Deficiency in Parkinson’s Disease
    Parkinson’s disease is characterized by degeneration of dopaminergic neurons in the substantia nigra.
  2. Role of Levodopa Therapy
    Levodopa is a dopamine precursor that crosses the blood–brain barrier and is converted to dopamine in the CNS.
  3. Peripheral Metabolism of Levodopa
    In the periphery, levodopa is metabolized by:
    • Aromatic L-amino acid decarboxylase (AADC)
    • Catechol-O-methyltransferase (COMT)
  4. Action of COMT Enzyme
    COMT converts levodopa to 3-O-methyldopa (3-OMD), an inactive metabolite that competes with levodopa for transport across the blood–brain barrier.
  5. Selective Peripheral COMT Inhibition
    Entacapone selectively inhibits peripheral COMT (does not significantly cross the BBB).
  6. Reduced Formation of 3-O-Methyldopa
    Inhibition of COMT decreases levodopa degradation in the periphery.
  7. Increased Plasma Half-life of Levodopa
    Higher and more sustained levodopa levels are available for CNS uptake.
  8. Enhanced Central Dopamine Availability
    More levodopa reaches the brain and is converted to dopamine, improving motor control.
  9. Reduction of “Wearing-Off” Effect
    Prolonged dopaminergic stimulation reduces motor fluctuations.
Mechanism of action of entacapone
Entacapone pharmacology
Entacapone pharmacology
Mechanism of action of entacapone
Entacapone Mechanism of Action Flowchart
Stepwise mechanism of action of entacapone

Pharmacokinetics

  • Absorption: Rapid oral absorption
  • Bioavailability: Moderate
  • Distribution: Limited CNS penetration
  • Metabolism: Extensive hepatic metabolism
  • Elimination: Fecal excretion
  • Half-life: Short (~0.5–2 hours)
  • Special note: Always administered with levodopa–carbidopa

Clinical Uses

Entacapone is used exclusively as adjunct therapy in Parkinson’s disease:

  • Parkinson’s disease with motor fluctuations
  • End-of-dose “wearing-off” phenomenon
  • To enhance and prolong levodopa response

Entacapone has no antiparkinsonian effect when used alone.

Adverse Effects

Adverse effects are mainly related to increased dopaminergic activity:

  • Dyskinesia
  • Nausea and vomiting
  • Diarrhea (common)
  • Abdominal pain
  • Orthostatic hypotension
  • Harmless brownish-orange discoloration of urine

Rare but important:

  • Hepatotoxicity (much less than tolcapone)

Comparative Analysis (must include a table + explanation)

Comparison of COMT Inhibitors

FeatureEntacaponeTolcapone
Site of actionPeripheral COMTCentral + peripheral COMT
BBB penetrationNoYes
Hepatotoxicity riskLowHigh
Monitoring requiredNoYes (LFTs)
Clinical useCommonly usedRestricted use

Explanation:
Entacapone is preferred over tolcapone due to its safer profile and lack of significant hepatotoxicity. Tolcapone is more potent but requires strict liver function monitoring.

MCQs (10–15)

  1. Entacapone inhibits which enzyme?
    a) MAO-B
    b) DOPA decarboxylase
    c) COMT
    d) Tyrosine hydroxylase

Answer: c) COMT

  1. Entacapone primarily acts in the:
    a) Brain
    b) Spinal cord
    c) Peripheral tissues
    d) Basal ganglia

Answer: c) Peripheral tissues

  1. Entacapone is always given with:
    a) Bromocriptine
    b) Selegiline
    c) Levodopa
    d) Amantadine

Answer: c) Levodopa

  1. Entacapone reduces formation of:
    a) Dopamine
    b) DOPAC
    c) 3-O-methyldopa
    d) Homovanillic acid

Answer: c) 3-O-methyldopa

  1. Entacapone improves Parkinson’s symptoms by:
    a) Increasing dopamine synthesis
    b) Blocking dopamine receptors
    c) Prolonging levodopa action
    d) Inhibiting acetylcholine

Answer: c) Prolonging levodopa action

  1. A common adverse effect of entacapone is:
    a) Hepatitis
    b) Diarrhea
    c) Nephrotoxicity
    d) Agranulocytosis

Answer: b) Diarrhea

  1. Entacapone does NOT:
    a) Cross the blood–brain barrier
    b) Inhibit COMT
    c) Increase levodopa bioavailability
    d) Reduce peripheral levodopa metabolism

Answer: a) Cross the blood–brain barrier

  1. Entacapone is useful mainly for:
    a) Early Parkinson’s disease monotherapy
    b) Tremor-dominant Parkinson’s disease
    c) Wearing-off phenomenon
    d) Parkinson’s psychosis

Answer: c) Wearing-off phenomenon

  1. Urine discoloration with entacapone is:
    a) Dangerous
    b) Due to hematuria
    c) Benign
    d) Due to renal damage

Answer: c) Benign

  1. Which COMT inhibitor has higher hepatotoxic risk?
    a) Entacapone
    b) Tolcapone
    c) Both equally
    d) Neither

Answer: b) Tolcapone

FAQs (minimum 5)

  1. What is the primary mechanism of entacapone?
    Inhibition of peripheral COMT, reducing levodopa metabolism.
  2. Does entacapone cross the blood–brain barrier?
    No, it acts only peripherally.
  3. Why is entacapone combined with levodopa?
    To prolong levodopa’s effect and reduce motor fluctuations.
  4. Is entacapone effective alone?
    No, it has no effect without levodopa.
  5. Why does entacapone cause urine discoloration?
    Due to colored metabolites; it is harmless.
  6. Is liver monitoring required with entacapone?
    No, unlike tolcapone.

References

Print Friendly, PDF & EmailDownload

Leave a Comment